Drug repositioning offers the possibility of breathing new life into
pharmaceutical R&D. By recycling drug data, repositioning promises to boost
production, accelerate and derisk R&D, and enhance product life-cycle
The promise of drug repositioning is now driving Big Pharma and Biotech to
focus over 50% of its R&D activity into the approach. As the benefits of drug
repositioning are being realized by industry; it is vital that stakeholders
successfully navigate this challenging yet rewarding R&D paradigm.
This in-depth report delivers:
Analysis of the scientific and technological strategies driving drug
repositioning, successful business models, the role of Big Pharma and the
financial reward of strategic drug repositioning Identification of the major
challenges within strategic drug repositioning - examining the
proof-of-concept clinical trial, regulatory hurdles, intellectual property
barriers, selection of screening technologies and company organization
Clinical and commercial analysis of classic and recently-approved repositioned
products and key Phase III candidates
With around 2,000 Phase II and Phase III failed pipeline candidates typically
sitting idle in a typical pharma drug library, drug repositioning may
resurrect abandoned R&D programs. Success will recoup R&D costs and provide
novel, high-value product life-cycle management.
Arrowhead has identified over 50 specialist drug repositioning companies
offering unique screening technologies. It is essential that players adopt a
multi-disciplined approach by forming collaborations with specialists to gain
valid, fast results to unveil new commercial opportunities.
This report will enable you to:
Assess opportunities and risks influencing strategic drug repositioning R&D
Identify key repositioned products in late-phase development based on
sales forecasts to 2016, to maximize your product's commercial potential
Gain an impartial perspective of strategies that can be used to enhance
your product's performance in the drug repositioning arena
Key questions answered by this report:
Why is there a need for drug repositioning in the biopharmaceutical
What are the major rewards offered by strategic drug repositioning?
What are the major challenges involved in this paradigm; and how can they
Who are the key specialist players involved in the market and what
business models are they utilizing?
What lessons can investors learn from established repositioned brands?
What products have recently gained FDA approval and what developmental
pathway did they take?
How can players optimize strategic drug repositioning to maximize
What are the key leading products and pipeline candidates in the market?
How much revenue will the leading products and key pipeline agents reach
What financial rewards does the strategy provide?
What recommendations does Arrowhead provide for successful repositioning?
What does the future hold for the drug repositioning market?
Table of Contents
1 EXECUTIVE SUMMARY
1.1 Scope of Drug Repositioning
1.2 Methodology OF Drug Repositioning
1.3 The Need for Drug Repositioning
1.4 Key Challenges Involved in Drug Repositioning
1.5 Successful Drug Repositioning Business Models
1.6 Financial Analysis of the Drug Repositioning Market
2 INTRODUCTION TO THE DRUG REPOSITIONING CONCEPT
2.1 What is Drug Repositioning?
2.1.1 The Definition of Drug Repositioning
2.1.2 The Aims of Drug Repositioning
2.1.3 The History of Drug Repositioning
2.2 The Need for Drug Repositioning
2.2.1 Lack of Highly Effective Products for Numerous Indications
2.2.2 Safer Drugs are Needed
2.2.3 The Cost of R&D May be Greater than Thought
2.2.4 Industry Pipelines are Weak with Small Growth Rates
2.2.5 Low Attrition Rates in R&D
2.2.6 The Number of NME's Submissions are Falling, Leading to Fewer
2.2.7 Patent Expiries to Rise Over the Coming Years
2.3 Repositioned Drug Products with New Indications
3 SCIENTIFIC AND TECHNOLOGICAL STRATEGIES DRIVING DRUG REPOSITIONING
3.1 The Science of Drug Repositiong: On and Off Targeting
3.2 Overview of the Strategic Drug Repositioning R&D Process
3.3 Technological Advances are Driving Drug Repositioning
China Pharmaceutical Guidebook Series (3) 2013 - Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products